The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

At the end of 2023, the FDA approved Casgevy for sickle cell disease ... David Rueda, Imperial College London CRISPR relies on two primary components: a guide RNA (gRNA) of 17-24 nucleotides that ...

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

A guide RNA will target the specific sequence within ... Vertex Pharmaceutical presented impressive long-term data for its Casgevy treatment. 39 out of 42 patients with SCD were free from VODs ...

The approval of the first CRISPR-based therapy in late 2023—CRISPR Therapeutics and Vertex Pharmaceuticals’ Casgevy (exagamglogene ... the delivery of messenger RNA (mRNA) to HSPCs in ...

Vertex Pharmaceuticals (NASDAQ:VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business update on the product. The data showed 93% of treated patients ...